neoadjuvant immunotherapy of locally advanced upper urinary tract urothelial carcinoma
Showing 1 - 1 of 1
Neoadjuvant Immunotherapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma Trial in Shanghai (Tislelizumab)
Active, not recruiting
- Neoadjuvant Immunotherapy of Locally Advanced Upper Urinary Tract Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Dec 12, 2020